Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder.
Bacillus Calmette-Guerin has been established as one of the most active agents for the treatment of superficial transitional cell carcinoma of the bladder. Although complications do occur with this agent, they are usually transient and mild. Two cases are herein reported in which dystrophic calcification of the urinary bladder occurred following BCG therapy; one had a diffuse and severe complication. This complication can occur with other intravesical agents, and methods for management are reported.
Spirnak
J P
JP
Department of Radiology, Brooke Army Medical Center, Fort Sam Houston, Texas.
Lubke
W L
WL
Thompson
I M
IM
Lopez
M
M
D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D002114:Calcinosis / Q000209:etiology* / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D001745:Urinary Bladder Diseases / Q000209:etiology* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine